Project Updates and Milestones news (page 23)

22 May 2026

Boehringer Ingelheim: CHMP backs JASCAYD (nerandomilast) for IPF and PPF

CHMP recommends EU approval after Phase III FIBRONEER trials showed slowed FVC decline in IPF and PPF; oral preferential PDE4B inhibitor already authorised in multiple countries.
22 May 2026

MOL obtains U.S. license to continue NIS negotiations

OFAC granted a license to continue negotiations to acquire a majority stake in NIS until 6 June 2026; talks enter final phase—significant progress, but some terms remain to be settled.
22 May 2026

EU awards €400m to 65 projects to decarbonise industrial heat

Across 10 EEA countries, projects deploy heat pumps, resistance, solar thermal and hybrids in sectors like pulp, steel, glass and food - avoiding 6.6M tCO2 over 10 years. Grant deals expected H2 2026.
22 May 2026

Eli Lilly's Foundayo (orforglipron) reduces body weight up to 13% in adults 65+

Once-daily oral orforglipron can be taken any time without food/water restrictions; showed significant 72-week weight loss across ages and diabetes status; safety consistent; GI AEs common.
22 May 2026

Merck secures CHMP positive opinion for KEYTRUDA + Padcev in cisplatin‑ineligible resectable MIBC

CHMP backed perioperative regimen for cisplatin‑ineligible resectable MIBC after Phase 3 KEYNOTE‑905 showed significant EFS, OS and pCR gains; EC decision due by Q3 2026; FDA cleared Nov 2025.
22 May 2026

Novo Nordisk: CHMP recommends Wegovy pill (oral semaglutide), the first oral GLP‑1, for EU approval

Oral semaglutide showed 16.6% mean weight loss (OASIS4, adherent); SELECT data added to label for CV risk reduction; no drug-drug restrictions; planned launch outside US H2 2026.

The right choices in the European chemical industry

Save time with chemXplore Alpha

Learn more

← Previous Next →